Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia

被引:9
|
作者
Titaley, Christiana R. [1 ,2 ]
Damayanti, Rita [1 ,2 ]
Soeharno, Nugroho [1 ,2 ]
Mu'asyaroh, Anifatun [1 ,2 ]
Bradley, Mark [3 ]
Lynam, Tim [4 ]
Krentel, Alison [5 ,6 ]
机构
[1] Univ Indonesia, Ctr Hlth Res, Depok, West Java Provi, Indonesia
[2] Univ Indonesia, Fac Publ Hlth, Depok, West Java Provi, Indonesia
[3] GSK, NTDs Global Hlth Programs, Brentford, England
[4] Reflecting Soc Pty Ltd, Townsville, Qld, Australia
[5] Bruyere Res Inst, Ottawa, ON, Canada
[6] London Sch Hyg & Trop Med, London, England
来源
PARASITES & VECTORS | 2018年 / 11卷
关键词
Lymphatic filariasis; Mass drug administration (MDA); Drugs deliverer; Knowledge; Feedback; Indonesia; Community drug distributor; RURAL-AREAS; TAMIL-NADU; COVERAGE; INDIA; ELIMINATION; IMPACT; STRATEGIES; COMMUNITY; PROGRAM;
D O I
10.1186/s13071-018-2881-x
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Background: This research assesses knowledge amongst drug deliverers about the implementation of mass drug administration (MDA) for lymphatic filariasis (LF) in Agam District (West Sumatera Province), the City of Depok (West Java Province) and the City of Batam (Kepulauan Riau Province), Indonesia. Methods: A cross-sectional survey was conducted from January to March 2015 at these three sites. Respondents were identified using purposive sampling (i.e. cadre, health worker or community representatives). A total of 318 questionnaires were accepted for analysis. Three outcomes were assessed: knowledge about LF; knowledge about MDA implementation; and was informed about MDA coverage. Logistic regression analyses were employed to examine factors associated with these three outcomes. Results: Less than half of respondents were charactersised as having a high level of LF knowledge and less than half a high level of knowledge about MDA. The odds of having a high level of knowledge of LF was significantly lower in Batam City than Agam District, yet higher amongst health workers than cadres. Deliverers living in urban areas reported more feedback on MDA outcomes than in the rural district. Health workers received more feedback than cadres (P < 0.001). Deliverers perceived the difference between coverage (drug receipt) and compliance (drug ingestion) in the community. Conclusions: There are variations in knowledge about LF and MDA as well as feedback across drug deliverers in MDA across geographical areas. Adaptation of the MDA guidelines, supportive supervision, increasing the availability of supporting materials and directly-observed therapy might be beneficial to improve coverage and compliance in all areas.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India
    Nujum, Zinia T.
    INTERNATIONAL HEALTH, 2011, 3 (01): : 22 - 26
  • [22] Maintaining effective mass drug administration for lymphatic filariasis through in-process monitoring in Sierra Leone
    Hodges, Mary H.
    Sonnie, Mustapha
    Turay, Hamid
    Conteh, Abdulai
    MacCarthy, Florence
    Sesay, Santigie
    PARASITES & VECTORS, 2012, 5
  • [23] Surveillance for lymphatic filariasis after stopping mass drug administration in endemic districts of Togo, 2010–2015
    Monique Ameyo Dorkenoo
    Rachel Bronzan
    Degninou Yehadji
    Mawèke Tchalim
    Kossi Yakpa
    Santrao Etassoli
    Poukpessi Adjeloh
    Issaka Maman
    Yao Sodahlon
    Parasites & Vectors, 11
  • [24] ADVERSE REACTIONS FOLLOWING MASS DRUG ADMINISTRATION WITH DIETHYLCARBAMAZINE AND ALBENDAZOLE FOR LYMPHATIC FILARIASIS ELIMINATION IN WEST SUMATERA, INDONESIA
    Widiastuti, Dyah
    Kesuma, Agung Puja
    Jastal
    Kusrini, Ina
    Wijayanti, Siwi Pramatama Mars
    Dhewantara, Pandji Wibawa
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2021, 52 (01) : 1 - 10
  • [25] Elimination of lymphatic filariasis: current perspectives on mass drug administration
    Gyapong, John O.
    Owusu, Irene O.
    Vroom, Frances B. da-Costa
    Mensah, Ernest O.
    Gyapong, Margaret
    RESEARCH AND REPORTS IN TROPICAL MEDICINE, 2018, 9 : 25 - 33
  • [26] Impact of mass drug administration for elimination of lymphatic filariasis in Nepal
    Ojha, Chet Raj
    Joshi, Basant
    Prakash, Khagendra K. C.
    Dumre, Shyam Prakash
    Yogi, Keshav Kumar
    Bhatta, Bandana
    Adhikari, Tulasi
    Crowley, Kathryn
    Marasini, Babu Ram
    PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (07):
  • [27] Perceived threat and benefit toward community compliance of filariasis' mass drug administration in Pekalongan district, Indonesia
    Widjanarko, Bagoes
    Saraswati, Lintang Dian
    Ginandjar, Praba
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2018, 11 : 189 - 197
  • [28] Prevalence of lymphatic filariasis in a tea garden worker population of Dibrugarh (Assam), India after six rounds of mass drug administration
    Khan, A. M.
    Dutta, P.
    Sarmah, C. K.
    Baruah, N. K.
    Das, S.
    Pathak, A. K.
    Sarmah, P.
    Hussain, M. E.
    Mahanta, J.
    JOURNAL OF VECTOR BORNE DISEASES, 2015, 52 (04) : 314 - 320
  • [29] No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds
    Coulibaly, Yaya Ibrahim
    Sangare, Moussa
    Dolo, Housseini
    Soumaoro, Lamine
    Coulibaly, Siaka Yamoussa
    Dicko, Ilo
    Diabate, Abdoul Fatao
    Diarra, Lamine
    Coulibaly, Michel Emmanuel
    Doumbia, Salif Seriba
    Diallo, Abdallah Amadou
    Dembele, Massitan
    Koudou, Benjamin G.
    Bockarie, Moses John
    Kelly-Hope, Louise A.
    Klion, Amy D.
    Nutman, Thomas B.
    PARASITOLOGY RESEARCH, 2022, 121 (11) : 3243 - 3248
  • [30] Mass drug administration to eliminate lymphatic filariasis: A population-based coverage and compliance study in Eastern India
    Mohanty, Shubhashisha
    Behera, Birasen
    Sinha, Abhinav
    Bal, Madhusmita
    Pati, Sanghamitra
    Sahoo, Prakash Kumar
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2024, 30